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Letter to the Editor
External validation of ADNEX model for
diagnosing ovarian cancer: evaluating performance
of differentiation between tumor subgroups
I would like to thank Araujo1 and Meys2 and their
colleagues for their validation studies of the ADNEX
model. For women with at least one persistent adnexal
mass who are scheduled for surgery, the ADNEX model
can predict their risk of having one of five different types of
adnexal mass: benign, borderline, Stage I ovarian cancer
(OC), Stage II–IVOC and secondary metastatic OC3. The
overall predicted risk of malignancy is obtained by adding
the predicted risks of the latter four subgroups. Despite
the fact that validation of a multinomial risk model is
not straightforward4, both research groups carried out
robust and well-reported studies. I have, however, some
observations regarding the methodology and results of
their assessment of the performance of the ADNEXmodel
in differentiating between tumor subtypes. To this end, I
requested further data from the authors and I would like
to express my gratitude for their co-operation.
The area under the receiver–operating characteristics
curve (AUC) of the ADNEX model for discriminating
between benign and all malignant tumors can be obtained
by the standard approach, using the overall predicted risk
of malignancy. Using this method, the reported AUC was
0.925 by Araujo et al.1 and 0.93 by Meys et al.2, which
is in line with other validation studies of the ADNEX
model3,5.
Discrimination between tumor subgroups is of particu-
lar interest and several methods exist to calculate the AUC
for models differentiating between two tumor subgroups,
including the recommended ‘conditional risk’ method4.
For example, to obtain the AUC for models differenti-
ating between borderline vs Stage I OC, the conditional
Table 1 Areas under receiver–operating characteristics curves for differentiation between tumor subgroups as reported by Araujo et al.1 and
as recalculated after applying conditional risk method to same data
Tumor subgroups Araujo et al.1 Conditional risk method Difference
Benign vs borderline 0.83 (0.73–0.94) 0.80 (0.67–0.88) –0.03
Benign vs Stage I OC 0.88 (0.78–0.98) 0.94 (0.86–0.97) 0.06
Benign vs Stage II–IV OC 0.99 (0.98–1.00) 0.99 (0.88–> 0.99) 0.00
Benign vs metastatic 0.97 (0.93–1.00) 0.97 (0.89–0.99) 0.00
Borderline vs Stage I OC 0.64 (0.44–0.84) 0.64 (0.43–0.81) 0.00
Borderline vs Stage II–IV OC 0.97 (0.93–1.00) 0.93 (0.79–0.98) –0.04
Borderline vs metastatic 0.77 (0.60–0.95) 0.80 (0.57–0.92) 0.03
Stage I OC vs Stage II–IV OC 0.94 (0.87–1.00) 0.96 (0.83–0.99) 0.02
Stage I OC vs metastatic 0.64 (0.42–0.86) 0.71 (0.46–0.88) 0.07
Stage II–IV OC vs metastatic 0.89 (0.78–1.00) 0.95 (0.81–0.99) 0.06
Values in parentheses are 95% CI. OC, ovarian cancer.
risk for Stage I OC is defined as the risk for Stage I OC
divided by the sum of the risks for borderline and Stage
I OC. Then, after excluding patients with histology other
than borderline or Stage I OC, the AUC can be obtained
by standard procedures using the conditional risk.
Araujo and colleagues computed subgroup AUCs using
the overall risk of malignancy instead of the conditional
risk. The limitation of this is that the overall risk of
malignancy is the sum of the risks of all four malignant
subgroups, therefore incorporating risks for subgroups
that are not of interest. Furthermore, when one is, for
example, interested in the AUC for borderline vs Stage
I OC, the overall risk of malignancy incorporates the
risk for both subgroups. In this case, it is not clear
how the overall risk of malignancy can assess optimally
discrimination between these two subgroups. Table 1
shows the AUCs for each paired subgroup comparison
as reported by Araujo et al. and as obtained using
the conditional risk method. AUCs for five of the 10
subgroup comparisons were higher using the conditional
risk method and two were lower. On average, AUCs were
higher by 0.02 with the conditional risk method.
Meys and colleagues used the risk for only one of the
subgroups when assessing performance of the ADNEX
model for differentiating between subgroups (e.g. risk for
Stage I OC used when assessing discrimination between
borderline tumors and Stage I OC). The limitation here
is that two patients with the same risk for Stage I OC
can have very different risks for a borderline tumor
because there are a total of five subgroups. Table 2 shows
the AUCs for each paired comparison as reported by
Meys et al. and as obtained using the conditional risk
method. AUCs were higher for nine of the 10 subgroup
comparisons using the conditional risk method. The AUC
for borderline vs Stage I OC showed a substantial increase
from 0.60 to 0.79. On average, AUCs were higher by 0.06
with the conditional risk method.
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Table 2 Areas under receiver–operating characteristics curves for differentiation between tumor subgroups as reported by Meys et al.2 and
as recalculated after applying conditional risk method to same data
Tumor subgroups Meys et al.2 Conditional risk method Difference
Benign vs borderline 0.81 (0.75–0.86) 0.88 (0.81–0.92) 0.07
Benign vs Stage I OC 0.87 (0.84–0.91) 0.92 (0.87–0.96) 0.05
Benign vs Stage II–IV OC 0.97 (0.94–0.99) 0.97 (0.94–0.99) 0.00
Benign vs metastatic 0.93 (0.89–0.96) 0.96 (0.89–0.99) 0.03
Borderline vs Stage I OC 0.60 (0.44–0.74) 0.79 (0.62–0.90) 0.19
Borderline vs Stage II–IV OC 0.87 (0.78–0.93) 0.92 (0.83–0.96) 0.05
Borderline vs metastatic 0.90 (0.77–0.97) 0.96 (0.86–0.99) 0.06
Stage I OC vs Stage II–IV OC 0.82 (0.71–0.90) 0.85 (0.74–0.92) 0.03
Stage I OC vs metastatic 0.72 (0.53–0.86) 0.76 (0.55–0.89) 0.04
Stage II–IV OC vs metastatic 0.67 (0.55–0.78) 0.71 (0.53–0.84) 0.04
Values in parentheses are 95% CI. OC, ovarian cancer.
In conclusion, discrimination between tumor subgroups
using the ADNEX model was better than reported. In
fact, results are similar to the validation results in the
prospective ADNEX study3. Of course, given the low
prevalence of some tumor types (borderline, Stage I OC,
secondary metastasis) and heterogeneity between centers,
variation in results between individual centers is to be
expected.
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